{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T07:10:12Z","timestamp":1779261012510,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00210-023-02886-8","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T12:01:56Z","timestamp":1702555316000},"page":"3771-3780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of bolus administration and short-term infusion versus long-term infusion of doxorubicin in terms of cardiotoxicity and efficacy"],"prefix":"10.1007","volume":"397","author":[{"given":"Hamed","family":"Ghiami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5310-0537","authenticated-orcid":false,"given":"Navid","family":"Omidkhoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Seddigh-Shamsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8905-1781","authenticated-orcid":false,"given":"Omid","family":"Arasteh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"issue":"6","key":"2886_CR1","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/bjc.1993.256","volume":"67","author":"H Anderson","year":"1993","unstructured":"Anderson H, Hopwood P, Prendiville J, Radford JA, Thatcher N, Ashcroft L (1993) A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. Br J Cancer 67(6):1385\u20131390","journal-title":"Br J Cancer"},{"issue":"Suppl 4","key":"2886_CR2","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1007\/BF01613219","volume":"117","author":"H Anderson","year":"1991","unstructured":"Anderson H, Prendiville J, Thatcher N, Radford JA, Swindell R (1991) A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer. J Cancer Res Clin Oncol 117(Suppl 4):S139-140","journal-title":"J Cancer Res Clin Oncol"},{"key":"2886_CR3","doi-asserted-by":"crossref","unstructured":"Bielack SS, Erttmann R, Kempf-Bielack B, Winkler K (1996) Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer 32a(10):1652\u20131660","DOI":"10.1016\/0959-8049(96)00177-3"},{"issue":"5","key":"2886_CR4","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/pbc.24404","volume":"60","author":"TR Brown","year":"2013","unstructured":"Brown TR, Vijarnsorn C, Potts J, Milner R, Sandor GG, Fryer C (2013) Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study. Pediatr Blood Cancer 60(5):842\u2013848","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2886_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","volume":"55","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55(3):213\u2013220","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"2886_CR6","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","volume":"109","author":"D Cardinale","year":"2004","unstructured":"Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109(22):2749\u20132754","journal-title":"Circulation"},{"issue":"2","key":"2886_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0735-1097(00)00748-8","volume":"36","author":"D Cardinale","year":"2000","unstructured":"Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, Cinieri S, Martinelli G, Cipolla CM, Fiorentini C (2000) Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36(2):517\u2013522","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2886_CR8","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/1097-0142(19910915)68:6<1221::AID-CNCR2820680607>3.0.CO;2-R","volume":"68","author":"ES Casper","year":"1991","unstructured":"Casper ES, Gaynor JJ, Hajdu SI, Magill GB, Tan C, Friedrich C, Brennan MF (1991) A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 68(6):1221\u20131229","journal-title":"Cancer"},{"issue":"20","key":"2886_CR9","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","volume":"70","author":"HM Chang","year":"2017","unstructured":"Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH (2017) Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol 70(20):2536\u20132551","journal-title":"J Am Coll Cardiol"},{"key":"2886_CR10","doi-asserted-by":"crossref","unstructured":"Cranmer LD, Hess LM, Sugihara T, Muntz HG (2023) Cardiac events among patients with sarcoma treated with doxorubicin by method of infusion: a real-world database study. Cancer Rep (Hoboken) 6(1):e1681","DOI":"10.1002\/cnr2.1681"},{"issue":"1","key":"2886_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF00685876","volume":"32","author":"BJ Cusack","year":"1993","unstructured":"Cusack BJ, Young SP, Driskell J, Olson RD (1993) Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 32(1):53\u201358","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2886_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/sj.neo.7900096","volume":"2","author":"AW El-Kareh","year":"2000","unstructured":"El-Kareh AW, Secomb TW (2000) A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells. Neoplasia 2(4):325\u2013338","journal-title":"Neoplasia"},{"issue":"22","key":"2886_CR13","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1200\/JCO.2007.14.9401","volume":"26","author":"L Gianni","year":"2008","unstructured":"Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB (2008) Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 26(22):3777\u20133784","journal-title":"J Clin Oncol"},{"issue":"1","key":"2886_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/1097-0142(19890101)63:1<37::AID-CNCR2820630106>3.0.CO;2-Z","volume":"63","author":"GN Hortobagyi","year":"1989","unstructured":"Hortobagyi GN, Frye D, Buzdar AU, Ewer MS, Fraschini G, Hug V, Ames F, Montague E, Carrasco CH, Mackay B et al (1989) Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 63(1):37\u201345","journal-title":"Cancer"},{"issue":"3","key":"2886_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/oxfordjournals.annonc.a057719","volume":"1","author":"C Jasmin","year":"1990","unstructured":"Jasmin C, Gil-Delgado MA, Marino JP, Ecstein E, Descorps-Declere A, Misset JL (1990) Phase I-II constant infusion of adriamycin (doxorubicin) by ambulatory pump delivery system in heavily pretreated (including adriamycin) breast cancer patients. Ann Oncol 1(3):189\u2013193","journal-title":"Ann Oncol"},{"issue":"3","key":"2886_CR16","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.taap.2015.10.002","volume":"289","author":"H Kamendi","year":"2015","unstructured":"Kamendi H, Zhou Y, Crosby M, Keirstead N, Snow D, Bentley P, Patel N, Barthlow H, Luo W, Dragan Y, Bialecki R (2015) Doxorubicin: comparison between 3-h continuous and bolus intravenous administration paradigms on cardio-renal axis, mitochondrial sphingolipids and pathology. Toxicol Appl Pharmacol 289(3):560\u2013572","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"2886_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.7326\/0003-4819-96-2-133","volume":"96","author":"SS Legha","year":"1982","unstructured":"Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96(2):133\u2013139","journal-title":"Ann Intern Med"},{"key":"2886_CR18","first-page":"1","volume":"6","author":"J Li","year":"2020","unstructured":"Li J, Chang HM, Banchs J, Araujo DM, Hassan SA, Wagar EA, Yeh ETH, Meng QH (2020) Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin. Cardiooncology 6:1","journal-title":"Cardiooncology"},{"issue":"6","key":"2886_CR19","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1200\/JCO.2002.20.6.1677","volume":"20","author":"SE Lipshultz","year":"2002","unstructured":"Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE, Colan SD (2002) Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91\u201301 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 20(6):1677\u20131682","journal-title":"J Clin Oncol"},{"issue":"6","key":"2886_CR20","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1542\/peds.2012-0727","volume":"130","author":"SE Lipshultz","year":"2012","unstructured":"Lipshultz SE, Miller TL, Lipsitz SR, Neuberg DS, Dahlberg SE, Colan SD, Silverman LB, Henkel JM, Franco VI, Cushman LL, Asselin BL, Clavell LA, Athale U, Michon B, Laverdi\u00e8re C, Schorin MA, Larsen E, Usmani N, Sallan SE (2012) Continuous versus bolus infusion of doxorubicin in children with all: long-term cardiac outcomes. Pediatrics 130(6):1003\u20131011","journal-title":"Pediatrics"},{"issue":"1","key":"2886_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1200\/JCO.1983.1.1.24","volume":"1","author":"J Lokich","year":"1983","unstructured":"Lokich J, Bothe A, Zipoli T, Green R, Sonneborn H, Paul S, Philips D (1983) Constant infusion schedule for adriamycin: a phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system. J Clin Oncol 1(1):24\u201328","journal-title":"J Clin Oncol"},{"issue":"4","key":"2886_CR22","first-page":"259","volume":"19","author":"BL Lum","year":"1985","unstructured":"Lum BL, Svec JM, Torti FM (1985) Doxorubicin: alteration of dose scheduling as a means of reducing cardiotoxicity. Drug Intell Clin Pharm 19(4):259\u2013264","journal-title":"Drug Intell Clin Pharm"},{"issue":"2","key":"2886_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56(2):185\u2013229","journal-title":"Pharmacol Rev"},{"issue":"3","key":"2886_CR24","doi-asserted-by":"publisher","first-page":"334","DOI":"10.4103\/0028-3886.115101","volume":"61","author":"SS Mishra","year":"2013","unstructured":"Mishra SS, Senapati SB, Dhir MK, Das S, Burma S (2013) A case of primary skull lymphoma: review of literature. Neurol India 61(3):334\u2013336","journal-title":"Neurol India"},{"issue":"5","key":"2886_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/BF00735923","volume":"32","author":"C Muller","year":"1993","unstructured":"Muller C, Chatelut E, Gualano V, De Forni M, Huguet F, Attal M, Canal P, Laurent G (1993) Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother Pharmacol 32(5):379\u2013384","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2886_CR26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1023\/A:1008334913109","volume":"11","author":"I Popov","year":"2000","unstructured":"Popov I, Jeli\u0107 S, Radulovi\u0107 S, Radosavljevi\u0107 D, Nikoli\u0107-Toma\u0161evi\u0107 Z (2000) Eight-hour infusion versus bolus injection of doxorubicin in the EAP regimen in patients with advanced gastric cancer: A prospective randomised trial. Ann Oncol 11(3):343\u2013348","journal-title":"Ann Oncol"},{"issue":"2","key":"2886_CR27","first-page":"145","volume":"3","author":"L Seymour","year":"1999","unstructured":"Seymour L, Bramwell V, Moran LA (1999) Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 3(2):145\u2013159","journal-title":"Cancer Prev Control"},{"issue":"4","key":"2886_CR28","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/1097-0142(19900215)65:4<870::AID-CNCR2820650407>3.0.CO;2-D","volume":"65","author":"J Shapira","year":"1990","unstructured":"Shapira J, Gotfried M, Lishner M, Ravid M (1990) Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer 65(4):870\u2013873","journal-title":"Cancer"},{"issue":"1","key":"2886_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40360-020-00417-2","volume":"21","author":"C Siebel","year":"2020","unstructured":"Siebel C, W\u00fcrthwein G, Lanvers-Kaminsky C, Andr\u00e9 N, Berthold F, Castelli I, Chastagner P, Doz F, English M, Escherich G, Fr\u00fchwald MC, Graf N, Groll AH, Ruggiero A, Hempel G, Boos J (2020) Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure. BMC Pharmacol Toxicol 21(1):37","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"2886_CR30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/0002-9343(85)90395-X","volume":"78","author":"JL Speyer","year":"1985","unstructured":"Speyer JL, Green MD, Dubin N, Blum RH, Wernz JC, Roses D, Sanger J, Muggia FM (1985) Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. Am J Med 78(4):555\u2013563","journal-title":"Am J Med"},{"issue":"6","key":"2886_CR31","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/BF00257439","volume":"24","author":"G Storm","year":"1989","unstructured":"Storm G, van Hoesel QG, de Groot G, Kop W, Steerenberg PA, Hillen FC (1989) A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou\/M Wsl rat. Cancer Chemother Pharmacol 24(6):341\u2013348","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4 Suppl 10","key":"2886_CR32","first-page":"43","volume":"25","author":"SM Swain","year":"1998","unstructured":"Swain SM (1998) Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin Oncol 25(4 Suppl 10):43\u201347","journal-title":"Semin Oncol"},{"issue":"1","key":"2886_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00007691-198901000-00002","volume":"11","author":"TW Sweatman","year":"1989","unstructured":"Sweatman TW, Lokich JJ, Israel M (1989) Clinical pharmacology of continuous infusion doxorubicin. Ther Drug Monit 11(1):3\u20139","journal-title":"Ther Drug Monit"},{"issue":"4","key":"2886_CR34","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/BF00685539","volume":"28","author":"CJ Twelves","year":"1991","unstructured":"Twelves CJ, Dobbs NA, Aldhous M, Harper PG, Rubens RD, Richards MA (1991) Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother Pharmacol 28(4):302\u2013307","journal-title":"Cancer Chemother Pharmacol"},{"key":"2886_CR35","doi-asserted-by":"crossref","unstructured":"van Dalen EC, Rapha\u00ebl MF, Caron HN, Kremer LC (2014) Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database Syst Rev(9): Cd006647","DOI":"10.1002\/14651858.CD006647.pub4"},{"issue":"9","key":"2886_CR36","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","volume":"64","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa P, Yeh ET (2014) Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 64(9):938\u2013945","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2886_CR37","doi-asserted-by":"publisher","first-page":"480","DOI":"10.5435\/JAAOS-21-08-480","volume":"21","author":"BE Walczak","year":"2013","unstructured":"Walczak BE, Irwin RB (2013) Sarcoma chemotherapy. J Am Acad Orthop Surg 21(8):480\u2013491","journal-title":"J Am Acad Orthop Surg"},{"issue":"13","key":"2886_CR38","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/jnci\/83.13.926","volume":"83","author":"M Zalupski","year":"1991","unstructured":"Zalupski M, Metch B, Balcerzak S, Fletcher WS, Chapman R, Bonnet JD, Weiss GR, Ryan J, Benjamin RS, Baker LH (1991) Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 83(13):926\u2013932","journal-title":"J Natl Cancer Inst"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02886-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-023-02886-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02886-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T08:22:20Z","timestamp":1716366140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-023-02886-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2886"],"URL":"https:\/\/doi.org\/10.1007\/s00210-023-02886-8","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"6 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}